, Jan. 8, 2020
/PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 2:30 pm.
Westin St. Francis Hotel, San Francisco
, CA Presentation Room:
Elizabethan DDate/Time: Tuesday, January 14
at 2:30pm PST
About Corvidia Therapeutics Inc.
Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for atherosclerotic cardiovascular disease (ASCVD) and inflammation in chronic kidney disease (CKD) patients, and high triglyceride-induced acute pancreatitis (AP). Founded in 2015, Corvidia Therapeutics is headquartered in Waltham, Massachusetts
. Learn more at: www.corvidiatx.com.
McDougall Communications on behalf of Corvidia Therapeutics Inc.
, email@example.com, Tel: +1 (585) 435-7379 Christopher Knospe
, firstname.lastname@example.org, Tel: +1 (716) 440-5580
View original content:http://www.prnewswire.com/news-releases/corvidia-therapeutics-to-participate-in-38th-annual-jp-morgan-healthcare-conference-300983087.html
SOURCE Corvidia Therapeutics Inc.